JohnRichertMD

PubMed

• 34 citations
  Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
  Riley Bove, Charles C. White, Gavin Giovannoni, Bonnie I. Glanz, Victor Golubchikov
  Neurology(R) Neuroimmunology & Neuroinflammation. 2015-12-01
• 133 citations
  Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
  Charlotte E. Teunissen, Til Menge, Ayse Altintas, José C. Álvarez-Cermeño, Antonio Bertolotto
  Multiple Sclerosis. 2013-05-21
• 173 citations
  Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens.
  Steven Jacobson, John R. Richert, William E. Biddison, A Satinsky, Robert J. Hartzman
  Journal of Immunology. 1984-08-01

Journal Articles

• Serum IL-17F does not predict poor response to IM IFNbeta- 1a in relapsing remitting MS.  
  Bushnell, S.E., Zhao, Z., Stebbins, C.C., Cadavid, D., Buko, A.M., Whalley, E., Davis, J.A., Versage, E., Richert, J., Axtell, R., Steinman, L., Medori, R., Neurology, 1/1/2012
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.  
  Fox, R.J. and the CONFIRM Study Investigators, N Eng J Med, 1/1/2012
• Placebo-controlled phase 3study of oral BG-12 for relapsing multiple sclerosis.  
  Gold, R. and the DEFINE Study Investigators, N Eng J Med, 1/1/2012
• Revisiting the Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.  
  Ontaneda, D. and the NMSS Task Force on Clinical Disability Measures, Mult Scler J, 1/1/2012
• Short-term relapse quantitation as a fully surrogate endpoint for long-term sustained progression of disability in RRMS patients treated with natalizumab.  
  Wang, Y-C., Sandrock, A.W., Richert, J.R., Meyerson, L., Miao, X, Neurol Res, 1/1/2011
• Stem cell transplantation in multiple sclerosis: current status and future prospects.  
  Martino, G., Franklin, R.J.M., Van Evercooren A.B., Kerr, D.A., and the Stem Cells in Multiple Sclerosis (STEMS) Consensus Group, Nat Rev Neurol, 1/1/2010
• Proof of concept studies for tissue-protective agents in multiple sclerosis.  
  Mehta, L.R., Schwid, S.R., Arnold, D.L., Cutter, G.R., Aradhye, S., et al, Multiple Sclerosis, 1/1/2009
• The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINAL.  
  Hutchinson, M. and the AFFIRM and SENTINAL Investigators, J Neurol, 1/1/2009
• Expert Opinion Paper: Recommendations regarding corticosteroids in the management of multiple sclerosis.  
  Panitch, H. and the Corticosteroid Use in Multiple Sclerosis Task Force, Publication of the National Clinical Advisory Board of the National Multiple Sclerosis Society, 1/1/2008
• Ethics of Placebo-Controlled Clinical Trials in Multiple Sclerosis: A reassessment.  
  Polman, C.H., Reingold, S.C., Barkhof, F., Calabresi, P.A., Clanet, M., Cohen, J.A., Cutter, G.R., et al., Neurology, 1/1/2008
• Differential Diagnosis of Suspected Multiple Sclerosis: A Consensus Approach.  
  Miller, D.H., Weinshenker, B.G., Filippi, M., Banwell,, B.L., Cohen, J.A., et al, Mult Scler, 1/1/2008
• Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.  
  Balcer, L.J. and the AFFIRM and SENTINEL Investigators, Neurology, 1/1/2007
• The incidence and significance of antinatalizumab antibodies. Results from AFFIRM and SENTINEL.  
  Calabresi, P.A. and the AFFIRM and SENTINEL Investigators, Neurology, 1/1/2007
• Health-related quality of life in multiple sclerosis: Effects of natalizumab.  
  Rudick, R.A. and the AFFIRM and SENTINEL Investigators, Ann Neurol, 1/1/2007
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.  
  Rudick, R.A. and the Sentinel Investigators, N Eng J Med, 1/1/2006
• IM interferon Beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.  
  CHAMPIONS Study Group, Neurology, 1/1/2006
• Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.  
  Frohman, E.M., Havrdova, E., Lublin, F., Barkhof, F., Achiron, A., Sharief, M.K., Stuve, O., Racke, M.K., Steinman, L., Weiner, H., Olek, M., Zivadinov, R., Corboy, J...., Arch Neurol, 1/1/2006
• Overcoming Challenges in Diagnosing MS.  
  Richert, J.R., Physician's Weekly, 1/1/2006
• Deletion of the SSK1 response regulator gene in Candida albicans contributes to enhanced killing by human polymorphonuclear neutrophils.  
  Du C., Richert, J., Calderone, R, Inf Immun, 1/1/2005
• Eight-year immunogenicity and safety of interferon beta-1a (Avonex) treatment in patients with multiple sclerosis.  
  Herndon, R.M., Rudick, R.A., Munschauer, F.E., Mass, M.K., Salazar, A.M., Coats, M.E., Labutta, R., Richert, J.R., Cohan, S.L., Genain, C., Goodkin, D., Toal, M., Ries..., Mult Sclerosis, 1/1/2005
• A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis.  
  Castro, H.J., Mendez-Inocencio J.I., Omidvar, B., Omidvar, J., Santilli, J., Nielsen, H.S., Pavot, A.P., Richert, J.R., Bellanti, J.A., Allergy and Asthma Proc, 1/1/2005
• Role of an internal ribosome entry site in the translational control of the human transcription factor Sp3.  
  Hernandez, E.M., Chan, C.H., Xu, B., Notario, V., Richert, J.R, J Oncol, 1/1/2004
• Human transcription factor Sp3: Genomic structure, identification of a processed pseudogene, and transcript analysis.  
  Moran, K.M., Crusio, R.H.J., Chan, C.H., Grekova, M.C., Richert, J.R., Gene, 1/1/2004
• Structure-based discovery of non-peptide small molecules to block the T cell response to myelin basic protein.  
  Koehler, N.K.U., Yang, C-Y., Varady, J., Lu, Y., Wu, X-w., Liu, M., Yin, D., Bartels, M., Xu, B-y., Roller, P.P., Long, Y-q., Li, P., Kattah, M., Cohn, M.L., Moran, K...., J Med Chem, 1/1/2004
• Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.  
  Stuart, W.H., Cohan, S., Richert, J.R., Achiron, A., Inf Immun, 1/1/2004
• Join now to see all

Books/Book Chapters

• Multiple Sclerosis Therapeutics. 
  Chapter: Preface to the Third Edition. 
  Richert, J.R.Editors: Cohen, J.A. and Rudick, R.A..Informa UK Ltd, Abingdon, UKEdition 3rd,2007
• Kelly's Textbook of Internal Medicine. 
  Chapter: Demyelinating Diseases. 
  Page 2912 - 2915Richert, J.R.Editors: Humes, H.D..Lippincott-Williams & Wilkens, Philadelphia, PAEdition 4th,2000
• Textbook of Internal Medicine. 
  Chapter: Demyelinating Diseases. 
  Page 2385 - 2388Richert, J.R.Editors: Kelley, W.N..Lippincott-Raven, Philadelphia, PAEdition 3rd,1997
• The Antigen T Cell Receptor. Selected Protocols and Applications. 
  Chapter: Construction and Expression of Human TCR Chains in Murine Hybridoma T Cell Lines. 
  Page 632 - 670Hastings, A.E., Richert, J.REditors: Oksenberg, J.R..Landes Bioscience, Austin, TX1997
• Myelin: Biology and Chemistry. 
  Chapter: Human T cell recognition of myelin basic protein peptides. 
  Page 833 - 847Richert, J.R.Editors: Martenson, R.E..CRC Press, Boca Raton, FL1992
• Current Concepts in Multiple Sclerosis. 
  Chapter: Molecular analysis of the recognition of myelin basic protein by cytotoxic T cells. 
  Page 315 - 320Martin, R., Olson, R., Howell, M., Jaraquemada, D., Flerlage, M., Richert, J., Karr, R., Brostoff, S., McFarlin, D.E., McFarland, H.F.Editors: Wietholter, H..Elsevier, Amsterdam1991
• Join now to see all

Abstracts/Posters

• Serum IL-17 levels not confirmed as predictors of non-response to IFN beta in RRMS in a large verification cohort.
  Bushnell, S., Whalley, E., Zhao, J., Buko, A., Versage, E., Stebbins, C., Davis, J., Cadavid, D., Richert, J., Axtel, R., Steinman, L., Medori, R, Triennial meeting of ECTRIMS/ACTRIMS/ LACTRIMS, Amsterdam, Netherlands, 10/21/2011
• Discovery of serum biomarkers of response to IFN beta-1a in RRMS: Analysis of inflammation proteins.
  Whalley, E., Zhao, J., Buko, A., Versage, E., Stebbins, C., Davis, J., Cadavid, D., Carulli, J., Richert, J., Medori, R., Bushnell, S., Annual meeting of American Academy of Neurology, Honolulu, HI, 4/13/2011
• Immune regulation in T cells by transcription factor Sp3: Implications for multiple sclerosis
  Schwechter, A., Grekova, M., Ressom, H., Notario, V., Richert, J, American Assn. of Immunologists Annual Meeting, Boston, MA, 5/14/2006
• Sp3 gene transcription is suppressed in MS immune cells.
  Grekova, M.C., Chen L.N., Chulikavit, M., Richert, J.R., Experimental Biology (AAI), Washington, DC, 4/21/2004
• Initial Results of the CHAMPIONS study, an open label 5-year extension of the CHAMPS study.
  Kinkel, R.P. and the CHAMPIONS study Group, 19th Congress of the European Committee for Treatment and Research in MS, Milan, 9/20/2003
• Decreased expression of the transcription factor Sp3 in MS immune cells is due to suppression at the transcriptional level.
  Grekova, M.C., Richert, J.R., 19th Congress of the European Committee for Treatment and Research in MS, Milan, 9/18/2003
• Characterization of the Sp3 gene: genomic structure, a novel processed pseudogene, and multiple transcripts.
  Moran, K.M., Chan, C., Crusio, R., Richert, J.R., Experimental Biology (ASBMB), San Diego, CA, 4/15/2003
• A new gene over-expressed in multiple sclerosis immune cells.
  Greene, C., Chen, L., Grekova, M., Connelly, D., Crusio, R., Rose, C., Saunders, C., Crayton, H., Jonklaas, J., Chutkan, R., Richert, J., Experimental Biology (ASBMB), San Diego, CA, 4/13/2003
• A new gene overexpressed in multiple sclerosis and rheumatoid arthritis.
  Greene, C., Crusio, R., Chen, L., Rose, C., Connelly, D., Grekova, M., Richert, J.R., Combined meeting of the European and Americas Committees for Treatment and Research in MS, Baltimore, MD, 9/20/2002
• A new gene overexpressed in multiple sclerosis.
  Greene, C., Grekova, M., Crusio, R., Rose, C., Mowry, E., Chen, L., Connelly, D., Richert, J., FASEB, New Orleans, LA, 4/24/2002
• Inhibition of binding of myelin basic protein 83-97 to HLA-DR1501 by small organic molecules.
  Xu, B-y., Hu Z., Varady, J., Wucherpfennig, K., Wang, S., Richert, J., 126th annual meeting of the American Neurological Association, Chicago, IL, 10/1/2001
• Inhibition of binding of MBP 83-97 to HLA-DR1501 by small organic molecules.
  Xu, B-y., Hu, Z, Varady, J., Wucherpfennig, K., Wang, S., Richert, J, 11th International Congress of Immunology, Stockholm, Sweden, 7/27/2001
• Three-dimensional modeling of a myelin basic protein-specific human T cell receptor.
  Richert, J.R., Wu, X-w., Robinson, E.D., Kattah, M., Bredy, B., Varady, J., Wang, S, Ann Neurol, 1/1/2000
• Identification of HLA-binding small non-peptide molecules that block the T cell response to MBP.
  Richert, J., Köhler, N., Wu, X-w., Liu, M., Bartels, M., Kattah, M., Roller, P., Long, Y-q., Cohn, M., Robinson, E., Wang, S., Presented at the combined meeting of the European and American Committees for Treatment and Research in MS, Basel, Switzerland, 9/17/1999
• Competitive PCR for quantitation of Sp3 mRNA in PBMC.
  Grekova, M., Salerno, K., Richert, J., Fourth Annual Symposium on Genomic Approaches to Target Selection and Validation for Drug Discovery, Jolla, CA, 2/11/1999
• Differential gene expression in MS immune cells.
  Richert, J.R., J Neurovirol, 1/1/1999
• Use of HLA-binding small molecules to block the T cell response to MBP.
  Richert, J., Kohler, N., Wu, X-w., Liu, M., Bartels, M., Kattah, M., Roller, P., Long, Y-q., Cohn, M., Robinson, E., Wang, S., The FASEB J, 1/1/1999
• CSF kappa light chains and gadolinium-enhancing brain lesions as predictors of response to therapy with interferon Beta-1a in patients with relapsing MS.
  Rudick, R., Cookfair, D., Simon, J., Simonian, N., Jacobs, L., Herndon, R., Richert, J., Salazar, A., and the MS Collaborative Research Group, 50th Annual meeting of the American Academy of Neurology, Minneapolis, MN, 4/30/1998
• Neuropsychological effects of Avonex (interferon Beta-1a) in relapsing MS.
  Fischer, J., Priore, R., Jacobs, L., Cookfair, D., Rudick, R., Herndon, R., Richert, J., Salazar, A., Goodkin, D., and the MS Collaborative Research Group, 50th Annual meeting of the American Academy of Neurology, Minneapolis, MN, 4/28/1998
• Phase 3 North American Trial of Roquinimex (Linomide) in relapsing-remitting and secondary progressive MS.
  Noseworthy, J., Wolinsky, J., Lublin, F., Whitaker, J., and the North American Linomide Trialists, 50th Annual meeting of the American Academy of Neurology, Minneapolis, MN, 4/28/1998
• Phase III North American Trial of roquinimex (Linomide) in relapsing-remitting and secondary progressive MS: MRI findings.
  Wolinsky J., Ponnada, A., and the North American Linomide Trialists, 50th Annual meeting of the American Academy of Neurology, Minneapolis, MN, 4/28/1998
• Deficient expression of the transcription factor Sp3 in MS immune cells. Keystone Symposium on Transcriptional Mechanisms.
  Grekova, M.C., Salerno, K., McFarland, H.F., Richert, J.R., Keystone Symposium on Transcriptional Mechanisms, Taos, NM, 2/24/1998
• Competitive PCR for quantitation of Sp3 mRNA in PBMC.
  Grekova, M., Salerno, K., Richert, J., 4th annual Symposium on Gene Quantitation: Clinical Applications and Drug Development, San Diego, CA, 2/8/1998
• Functional blocking of HLA molecules with organic non-peptide compounds screened by computer modeling: inhibition of the T cell response to myelin basic protein.
  Kohler, N., Wang, S., Liu, M., Yin, D., Wu, X-W., Richert, J., Neurology, 1/1/1998
• Deficient expression of the transcription factor Sp3 in MS immune cells.
  Grekova, M.C., Salerno, K., Das, S., Richert, J.R., J Neuroimmunology, 1/1/1998
• Join now to see all

Lectures

• Fast Forward Think Tank on Progressive MS 
  Boston, MA - 12/1/2010
• MS research opportunities in Australia and the need for more MS research funding. 
  Canberra. - 3/17/2009
• 11th Annual BioCEO & Investor Conference. 
  New York - 2/10/2009
• Hot-Topics 2: Genomics and Proteomics in Understanding MS. 
  Montreal, Quebec, Canada - 9/17/2008
• Parallel Session 10, Free Communications. 
  Prague, Czech Republic - 10/14/2007
• The role of abnormal Sp3 gene expression in MS. 
  10/12/2006
• Plenary Session 2. 
  Thessaloniki, Greece - 9/30/2005
• Future Directions in MS Research. 
  Houston, TX - 9/9/2005
• Gene expression studies in MS. 
  9/7/2005
• Abnormal gene expression in MS immune cells. 
  Portland - 12/11/2003
• Session on the Immune System. 
  Arlington, VA - 11/24/2003
• MS Outcomes: What to Measure and Why. 
  Wichita, KS - 6/30/2003
• Clinical Outcomes in the Phase III MS Trials. 
  St. Louis, MO - 6/28/2003
• Navigating the maze of therapeutic options in MS. 
  Honolulu, HI - 4/29/2003
• The role of genetics in MS. 
  Mahwah, NJ - 3/8/2003
• Hot Topics in Neuroimmunology. 
  Baltimore, MD - 9/20/2002
• Research Update. 
  Raleigh, NC - 5/7/2002
• The "SP's" of MS: Secondary Progressive MS (SPMS) and Sp3. 
  Baltimore, MD - 3/20/2002
• Future trends in MS treatment: combination therapy. 
  Scottsdale, AZ - 3/1/2002
• MS: Rationale for treatment of breakthrough disease. 
  Walter Reed Army Medical Center - 11/13/2001
• Treatment Options in MS. 
  Manassas, VA - 11/10/2001
• Treatment of secondary progressive MS and breakthrough disease. 
  10/26/2001
• New diagnostic and therapeutic methods for multiple sclerosis. 
  10/24/2001
• New data on current therapies for MS. 
  Des Moines, IA - 10/13/2001
• Worsening MS: New paradigms in treatment. 
  Los Angeles, CA - 8/7/2001
• Join now to see all

Other

• Topic: MS. 
  Richert JR, Interviewed by Dr. Frank Adams on "Doctor Radio" (Sirius Radio).
  8/24/2010
• Oral therapies for MS. 
  Richert JR, Interviewed on National Public Radio (NPR).
  1/20/2010
• New genetics studies in MS. 
  Richert JR, Interviewed on CNN.
  7/29/2007
• Advances in MS. 
  Richert JR, Interviewed on WMTV (NBC Channel 15)
  Milwaukee, WI - 5/23/2007
• Differential gene expression in MS immune cells. 
  Richert JR, Interviewed on WITI-TV (Fox channel 6)
  Gainesville, FL - 2/10/2007
• The use of stem cells in MS. 
  Richert JR, Interviewed on KGO (ABC 7 TV).
  San Francisco, CA - 1/17/2007
• Oral MS therapies in the pipeline. 
  Richert JR, Interviewed by CBS Radio.
  11/1/2006
• Cyclophosphamide treatment of MS. 
  Richert JR, Interviewed on Geraldo at Large (Fox News).
  9/19/2006
• Tysabri therapy for MS. 
  Richert JR, Interviewed on ABC Online.
  3/2/2006
• Pediatric MS. 
  Richert JR, Interviewed on CNN.
  3/1/2006
• Interview on MS. 
  Richert JR, Interviewed on WebMD.
  12/19/2005
• Interview on multiple sclerosis. 
  Richert JR, Interviewed on WSB-TV2
  Atlanta, GA - 11/10/2005
• Interview regarding MS. 
  Richert JR, Interviewed on National Public Radio "Public Interest with Kojo Nnamdi"
  12/6/2000
• Interview regarding newly published trial of interferon Beta in early MS. 
  Richert JR, WTOP News Radio
  Washington, DC - 10/20/2000
• The use of bee stings in the treatment of MS. 
  Richert JR, Interviewed on WUSA-TV
  Washington, DC - 5/4/2000
• The clinical trial of Linomide in the treatment of MS. 
  Richert JR, Interviewed on WUSA-TV
  Washington, DC - 12/3/1996
• New therapies in MS. 
  Richert JR, Interviewed on TV Channel 13
  Norfolk, VA - 11/1/1996
• The use of beta interferon for treatment of multiple sclerosis. 
  Richert JR, Interviewed on WRC-TV; Cable NewsChannel 8
  Washington, DC - 12/6/1995
• Beta interferon for the treatment of multiple sclerosis. 
  Richert JR, Interviewed on WUSA-TV
  Washington, DC - 8/7/1993
• The use of bee stings in MS. 
  Richert JR, Interviewed on Connie Chung's "Eye to Eye", CBS
  7/22/1993
• Commentary on the use of bee stings in the treatment of multiple. 
  Richert JR, Interviewed on WRC-TV
  Washington, DC - 5/24/1993
• Segment on Multiple Sclerosis. 
  Richert JR
  Washington, DC - 11/29/1990
• Multiple Sclerosis. 
  Richert JR, Interviewed on "Sonya-Live From LA", Cable News Network
  11/28/1989
• Join now to see all